株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

がん・腫瘍プロファイリングの世界市場 (技術別・手法別・用途別・地域別):市場規模・シェア・動向・成長率・需要の予測

Cancer/Tumor Profiling Market by Technology, by Technique, by Application, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023

発行 Prescient & Strategic Intelligence Private Limited 商品コード 600261
出版日 ページ情報 英文 161 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
がん・腫瘍プロファイリングの世界市場 (技術別・手法別・用途別・地域別):市場規模・シェア・動向・成長率・需要の予測 Cancer/Tumor Profiling Market by Technology, by Technique, by Application, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023
出版日: 2017年11月01日 ページ情報: 英文 161 Pages
概要

当レポートでは、世界のがん・腫瘍プロファイリングの市場について分析し、技術の概略や市場構造、主な市場促進・抑制要因、市場規模の実績値・予測値 (過去4年間・今後7年間分)、技術別・手法別・用途別および各地域・主要国市場の詳細動向、市場競争状態、主要企業のプロファイルなどを調査しております。

第1章 分析の背景事情

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 イントロダクション

  • 市場区分の定義
  • 市場のダイナミクス
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • ポーターのファイブフォース分析

第5章 世界市場の分析と予測

  • 技術別
    • ISH (in situハイブリッド形成法) 技術:種類別
  • 手法別
  • 用途別
  • 地域別

第6章 北米市場の分析と予測

第7章 欧州市場の分析と予測

第8章 アジア太平洋地域市場の分析と予測

第9章 ラテンアメリカ市場の分析と予測

第10章 中東・アフリカ市場の分析と予測

第11章 世界市場の分析と予測:技術別

  • NGS (次世代シークエンシング) 市場:地域別
  • QPCR (定量ポリメラーゼ連鎖反応) 市場:地域別
  • IHC (免疫組織化学) 市場:地域別
  • ISH (in situハイブリッド形成法) 市場:地域別
  • マイクロアレイ市場:地域別

第12章 世界市場の分析と予測:手法別

  • ゲノミクス市場:地域別
  • プロテオミクス市場:地域別
  • エピジェネティクス装置市場:地域別
  • メタボロミクス市場:地域別

第13章 世界市場の分析と予測:用途別

  • 個別化医療市場:地域別
  • 診断市場:地域別
  • バイオマーカー市場:地域別
  • 予後市場:地域別

第14章 競争環境

  • 主要企業の製品の比較分析
  • 主要企業の戦略展開状況
    • 製品の上市・認証
    • 合意、事業提携・協力
    • 設備拡張
    • その他の動き

第15章 企業プロファイル

  • Illumina, Inc.
    • 事業概要
    • 主要製品・サービス
    • 主な財務指標
    • 戦略的成長プラン
  • NeoGenomics Inc.
  • Caris Life Sciences, Inc.
  • QIAGEN N.V.
  • Helomics Corp.
  • Oxford Gene Technology
  • HTG Molecular Diagnostics, Inc.
  • RiboMed Biotechnologies, Inc.
  • Genomic Health, Inc.
  • NanoString Technologies, Inc.

第16章 付録

目次

Global cancer/tumor profiling market size is projected to achieve a value of $87.1 billion value by 2023, growing at a CAGR of 19.0% during 2017-2023.

The boost in demand for cancer/tumor profiling products is mainly led by increasing number of new cancer cases, rising utility of biomarkers in tumor profiling, rising availability of funding for cancer research and increasing demand for next generation sequencing for cancer profiling.

Insights on market segments

The cancer profiling market has been bifurcated into next generation sequencing (NGS), quantitative polymerase chain reaction (QPCR), immunohistochemistry (IHC), in-situ hybridization (ISH), and microarray, based on technology. NGS held the largest share in the cancer profiling market, standing at 33.1%, in 2016. This leading position of NGS is mainly characterized by increased awareness about NGS products due to rising promotional activities for these products among the research laboratories and academic institutes. The NGS category is also expected to grow at the highest CAGR during the forecast period.

ISH is further categorized into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). FISH held the larger share of the ISH technology market in 2016. The higher penetration of this technology is driven by increasing number of players offering FISH in cancer profiling market, such as Abbott Laboratories. FISH is also expected to observe the faster growth in future, with the CAGR likely to stand at 18.6% during the forecast period.

The various techniques used in the cancer profiling include genomics, proteomics, epigenetics, and metabolomics. Genomics held the largest share of 40.6% in 2016, and it is also expected to register highest growth during the forecast period, due to increasing implementation of genomic sequencing.

Cancer profiling is used in varied applications such as personalized medicine, diagnostics, biomarker discovery, prognostics, and others. In 2016, personalized medicine held largest share of 36.4% in the cancer profiling market, attributed to subsequent increasing adoption of personalized medicine for tumor profiling, since it is one of the most cost-effective methods. The application is also expected to register fastest growth during the forecast period.

Asia-Pacific is projected to register the fastest growth in cancer/tumor profiling market

The Asia-Pacific cancer profiling market has been experiencing significant growth due to rising prevalence of cancer, increasing government initiatives for cancer treatment, and rising healthcare expenditure in the region. According to the Indian Council of Medical Research (ICMR), around 14.5 lakhs of new cancer cases were registered in India in 2016, which is likely to reach nearly 17.3 lakh new cases, by 2020. This increase in cancer cases indicates that, the healthcare providers will require more profiling kits, thus increasing the demand for cancer/tumor profiling kits in the region.

Key competitors are introducing new and innovative products cancer/tumor profiling market

Globally, the key providers in the cancer profiling market are launching new products to gain a larger market share. In October 2017, QIAGEN N.V. launched custom solutions business, aimed at providing life sciences and molecular diagnostics companies with the tools and expertise required to quickly build and commercialize products that meet unique workflow requirements. In the same month, the company also launched ipsogen JAK2 RGQ PCR kit, an ipsogen JAK2 assay, an assay used for the detection of the JAK2 V617F/G1849T allele in genomic DNA extracted from EDTA whole blood.

Some of the other key players operating in the cancer profiling market include Illumina, Inc., NeoGenomics Inc., Caris Life Sciences, Inc., Helomics Corp., Oxford Gene Technology, HTG Molecular Diagnostics, Inc., RiboMed Biotechnologies, Inc., Genomic Health, Inc., and NanoString Technologies, Inc.

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Technology
    • 1.3.2 Market Segmentation by Technique
    • 1.3.3 Market Segmentation by Application
    • 1.3.4 Market Segmentation by Geography
    • 1.3.5 Analysis Period
    • 1.3.6 Market Data Reporting Unit
      • 1.3.6.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Technology
      • 4.1.1.1 NGS
      • 4.1.1.2 QPCR
      • 4.1.1.3 IHC
      • 4.1.1.4 ISH
        • 4.1.1.4.1 FISH
        • 4.1.1.4.2 CISH
      • 4.1.1.5 Microarray
    • 4.1.2 By Technique
      • 4.1.2.1 Genomics
      • 4.1.2.2 Proteomics
      • 4.1.2.3 Epigenetics
      • 4.1.2.4 Metabolomics
    • 4.1.3 By Application
      • 4.1.3.1 Personalized medicine
      • 4.1.3.2 Diagnostics
      • 4.1.3.3 Biomarker discovery
      • 4.1.3.4 Prognostics
      • 4.1.3.5 Others
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
      • 4.2.1.1 Increasing number of new cancer cases
      • 4.2.1.2 Rising utility of biomarkers in tumor profiling
      • 4.2.1.3 Rise in availability of funding for cancer research
      • 4.2.1.4 Increasing demand for next generation sequencing for cancer profiling
      • 4.2.1.5 Impact analysis of drivers on market forecast
    • 4.2.2 Restraints
      • 4.2.2.1 High capital investments and low benefit ratio for biomarkers
      • 4.2.2.2 Dearth of skilled professionals and infrastructure
      • 4.2.2.3 Impact analysis of restraints on market forecast
    • 4.2.3 Opportunities
      • 4.2.3.1 Increasing use of point-of-care diagnostic tests
      • 4.2.3.2 Rising demand for personalized medicine
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Buyers
    • 4.3.2 Bargaining Power of Suppliers
    • 4.3.3 Intensity of Rivalry
    • 4.3.4 Threat of New Entrants
    • 4.3.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast

  • 5.1 By Technology
    • 5.1.1 ISH Technology by Type
  • 5.2 By Technique
  • 5.3 By Application
  • 5.4 By Region

Chapter 6. North America Market Size and Forecast

  • 6.1 By Technology
  • 6.2 By Technique
  • 6.3 By Application
  • 6.4 By Country

Chapter 7. Europe Market Size and Forecast

  • 7.1 By Technology
  • 7.2 By Technique
  • 7.3 By Application
  • 7.4 By Country

Chapter 8. Asia-Pacific Market Size and Forecast

  • 8.1 By Technology
  • 8.2 By Technique
  • 8.3 By Application
  • 8.4 By Country

Chapter 9. LATAM Market Size and Forecast

  • 9.1 By Technology
  • 9.2 By Technique
  • 9.3 By Application
  • 9.4 By Country

Chapter 10. MEA Market Size and Forecast

  • 10.1 By Technology
  • 10.2 By Technique
  • 10.3 By Application

Chapter 11. Global Market Size and Forecast by Technology

  • 11.1 Global NGS Market, by Region
  • 11.2 Global QPCR Market, by Region
  • 11.3 Global IHC Devices Market, by Region
  • 11.4 Global ISH Market, by Region
  • 11.5 Global Microarray Market, by Region

Chapter 12. Global Market Size and Forecast by Technique

  • 12.1 Global Genomics Market, by Region
  • 12.2 Global Proteomics Market, by Region
  • 12.3 Global Epigenetics Devices Market, by Region
  • 12.4 Global Metabolomics Market, by Region

Chapter 13. Global Market Size and Forecast by Application

  • 13.1 Global Personalized Medicine Market, by Region
  • 13.2 Global Diagnostics Market, by Region
  • 13.3 Global Biomarker Discovery Market, by Region
  • 13.4 Global Prognostics Market, by Region

Chapter 14. Competitive Landscape

  • 14.1 Product Benchmarking of Key Players
  • 14.2 Global Strategic Developments of Key Players
    • 14.2.1 Product Launches and Approvals
    • 14.2.2 Agreements, Partnerships and Collaborations
    • 14.2.3 Facility Expansion
    • 14.2.4 Other Developments

Chapter 15. Company Profiles

  • 15.1 Illumina, Inc.
    • 15.1.1 Business Overview
    • 15.1.2 Product and Service Offerings
    • 15.1.3 Key Financial Summary
    • 15.1.4 Strategic Growth Plans
  • 15.2 NeoGenomics Inc.
    • 15.2.1 Business Overview
    • 15.2.2 Product and Service Offerings
    • 15.2.3 Key Financial Summary
    • 15.2.4 Strategic Growth Plans
  • 15.3 Caris Life Sciences, Inc.
    • 15.3.1 Business Overview
    • 15.3.2 Product and Service Offerings
    • 15.3.3 Strategic Growth Plans
  • 15.4 QIAGEN N.V.
    • 15.4.1 Business Overview
    • 15.4.2 Product and Service Offerings
    • 15.4.3 Key Financial Summary
    • 15.4.4 Strategic Growth Plans
  • 15.5 Helomics Corp.
    • 15.5.1 Business Overview
    • 15.5.2 Product and Service Offerings
    • 15.5.3 Strategic Growth Plans
  • 15.6 Oxford Gene Technology
    • 15.6.1 Business Overview
    • 15.6.2 Product and Service Offerings
    • 15.6.3 Strategic Growth Plans
  • 15.7 HTG Molecular Diagnostics, Inc.
    • 15.7.1 Business Overview
    • 15.7.2 Product and Service Offerings
    • 15.7.3 Key Financial Summary
    • 15.7.4 Strategic Growth Plans
  • 15.8 RiboMed Biotechnologies, Inc.
    • 15.8.1 Business Overview
    • 15.8.2 Product and Service Offerings
    • 15.8.3 Strategic Growth Plans
  • 15.9 Genomic Health, Inc.
    • 15.9.1 Business Overview
    • 15.9.2 Product and Service Offerings
    • 15.9.3 Key Financial Summary
    • 15.9.4 Strategic Growth Plans
  • 15.10 NanoString Technologies, Inc.
    • 15.10.1 Business Overview
    • 15.10.2 Product and Service Offerings
    • 15.10.3 Key Financial Summary
    • 15.10.4 Strategic Growth Plans

Chapter 16. Appendix

  • 16.1 Abbreviations
  • 16.2 Related Report

LIST OF TABLES

  • TABLE 1 ANALYSIS PERIOD OF THE STUDY
  • TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 4 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2016)
  • TABLE 5 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 - 2023)
  • TABLE 6 GLOBAL ISH TECHNOLOGY MARKET, BY TYPE, $M (2013 - 2016)
  • TABLE 7 GLOBAL ISH TECHNOLOGY MARKET, BY TYPE, $M (2017 - 2023)
  • TABLE 8 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2016)
  • TABLE 9 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 - 2023)
  • TABLE 10 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2016)
  • TABLE 11 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 - 2023)
  • TABLE 12 GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 13 GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 14 DIFFERENT TYPE OF CANCERS AND THE AMOUNT FUNDED
  • TABLE 15 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2016)
  • TABLE 16 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 - 2023)
  • TABLE 17 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2016)
  • TABLE 18 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 - 2023)
  • TABLE 19 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2016)
  • TABLE 20 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 - 2023)
  • TABLE 21 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 - 2016)
  • TABLE 22 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 - 2023)
  • TABLE 23 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2016)
  • TABLE 24 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 - 2023)
  • TABLE 25 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2016)
  • TABLE 26 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 - 2023)
  • TABLE 27 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2016)
  • TABLE 28 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 - 2023)
  • TABLE 29 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 - 2016)
  • TABLE 30 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 - 2023)
  • TABLE 31 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2016)
  • TABLE 32 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 - 2023)
  • TABLE 33 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2016)
  • TABLE 34 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 - 2023)
  • TABLE 35 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2016)
  • TABLE 36 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 - 2023)
  • TABLE 37 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 - 2016)
  • TABLE 38 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 - 2023)
  • TABLE 39 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2016)
  • TABLE 40 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 - 2023)
  • TABLE 41 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2016)
  • TABLE 42 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 - 2023)
  • TABLE 43 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2016)
  • TABLE 44 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 - 2023)
  • TABLE 45 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 - 2016)
  • TABLE 46 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 - 2023)
  • TABLE 47 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2016)
  • TABLE 48 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 - 2023)
  • TABLE 49 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2016)
  • TABLE 50 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 - 2023)
  • TABLE 51 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2016)
  • TABLE 52 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 - 2023)
  • TABLE 53 GLOBAL NGS MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 54 GLOBAL NGS MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 55 GLOBAL QPCR MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 56 GLOBAL QPCR MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 57 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 58 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 59 GLOBAL ISH MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 60 GLOBAL ISH MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 61 GLOBAL MICROARRAY MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 62 GLOBAL MICROARRAY MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 63 GLOBAL GENOMICS MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 64 GLOBAL GENOMICS MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 65 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 66 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 67 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 68 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 69 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 70 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 71 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 72 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 73 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 74 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 75 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 76 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 77 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2013 - 2016)
  • TABLE 78 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2017 - 2023)
  • TABLE 79 ILLUMINA, INC. - AT A GLANCE
  • TABLE 80 ILLUMINA, INC. - KEY FINANCIAL SUMMARY
  • TABLE 81 NEOGENOMICS INC.- AT A GLANCE
  • TABLE 82 NEOGENOMICS INC. - KEY FINANCIAL SUMMARY
  • TABLE 83 CARIS LIFE SCIENCES, INC.- AT A GLANCE
  • TABLE 84 QIAGEN N.V. - AT A GLANCE
  • TABLE 85 QIAGEN N.V. - KEY FINANCIAL SUMMARY
  • TABLE 86 HELOMICS CORP. - AT A GLANCE
  • TABLE 87 OXFORD GENE TECHNOLOGY - AT A GLANCE
  • TABLE 88 HTG MOLECULAR DIAGNOSTICS, INC. -AT A GLANCE
  • TABLE 89 HTG MOLECULAR DIAGNOSTICS, INC. - KEY FINANCIAL SUMMARY
  • TABLE 90 RIBOMED BIOTECHNOLOGIES, INC. - AT A GLANCE
  • TABLE 91 GENOMIC HEALTH, INC. - AT A GLANCE
  • TABLE 92 GENOMIC HEALTH, INC. - KEY FINANCIAL SUMMARY
  • TABLE 93 NANOSTRING TECHNOLOGIES, INC. - AT A GLANCE
  • TABLE 94 NANOSTRING TECHNOLOGIES, INC., - KEY FINANCIAL SUMMARY

LIST OF FIGURES

  • FIG 1 RESEARCH METHODOLOGY
  • FIG 2 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY REGION
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 6 DATA TRIANGULATION APPROACH
  • FIG 7 GLOBAL CANCER/TUMOR PROFILING MARKET SUMMARY
  • FIG 8 PORTER'S FIVE FORCES ANALYSIS
  • FIG 9 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2023)
  • FIG 10 GLOBAL ISH TECHOLOGY MARKET, BY TYPE, $M (2013 - 2023)
  • FIG 11 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2023)
  • FIG 12 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2023)
  • FIG 13 WORLDWIDE MAJOR MARKETS FOR CANCER/TUMOR PROFILING
  • FIG 14 NORTH AMERICA CANCER/TUMOR PROFILING MARKET SNAPSHOT
  • FIG 15 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2023)
  • FIG 16 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2023)
  • FIG 17 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2023)
  • FIG 18 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 - 2023)
  • FIG 19 EUROPE CANCER/TUMOR PROFILING MARKET SNAPSHOT
  • FIG 20 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2023)
  • FIG 21 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2023)
  • FIG 22 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2023)
  • FIG 23 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 - 2023)
  • FIG 24 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SNAPSHOT
  • FIG 25 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2023)
  • FIG 26 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2023)
  • FIG 27 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2023)
  • FIG 28 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 - 2023)
  • FIG 29 LATAM CANCER/TUMOR PROFILING MARKET SNAPSHOT
  • FIG 30 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2023)
  • FIG 31 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2023)
  • FIG 32 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2023)
  • FIG 33 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 - 2023)
  • FIG 34 MEA CANCER/TUMOR PROFILING MARKET SNAPSHOT
  • FIG 35 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 - 2023)
  • FIG 36 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 - 2023)
  • FIG 37 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 - 2023)
  • FIG 38 GLOBAL NGS MARKET, BY REGION, $M (2013 - 2023)
  • FIG 39 GLOBAL QPCR MARKET, BY REGION, $M (2013 - 2023)
  • FIG 40 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2013 - 2023)
  • FIG 41 GLOBAL ISH MARKET, BY REGION, $M (2013 - 2023)
  • FIG 42 GLOBAL MICROARRAY MARKET, BY REGION, $M (2013 - 2023)
  • FIG 43 GLOBAL GENOMICS MARKET, BY REGION, $M (2013 - 2023)
  • FIG 44 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2013 - 2023)
  • FIG 45 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2013 - 2023)
  • FIG 46 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2013 - 2023)
  • FIG 47 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2013 - 2023)
  • FIG 48 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2013 - 2023)
  • FIG 49 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2013 - 2023)
  • FIG 50 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2013 - 2023)
  • FIG 51 ILLUMINA, INC. - REVENUE SPLIT BY GEOGRAPHY (2016)
  • FIG 52 NEOGENOMICS INC. - REVENUE SPLIT BY SEGMENT (2016)
  • FIG 53 QIAGEN N.V. - REVENUE SPLIT BY GEOGRAPHY (2016)
  • FIG 54 HTG MOLECULAR DIAGNOSTICS, INC. - REVENUE SPLIT BY PRODUCT (2016)
  • FIG 55 HTG MOLECULAR DIAGNOSTICS, INC. - REVENUE SPLIT BY SERVICES (2016)
  • FIG 56 GENOMIC HEALTH, INC. - REVENUE SPLIT BY GEOGRAPHY (2016)
  • FIG 57 NANOSTRING TECHNOLOGIES, INC. - REVENUE SPLIT BY PRODUCT AND SERVICES (2016)
  • FIG 58 NANOSTRING TECHNOLOGIES, INC. - REVENUE SPLIT BY GEOGRAPHY (2016)
Back to Top